Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors

   
   

This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R.sup.1, L.sup.1, L.sup.2, V, L.sup.3, and R.sup.2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

Diese Erfindung bezieht auf einer pyrido[3,4-d]pyrimidine Ableitung von Formel I 1, oder ein pharmazeutisch annehmbares Salz davon, worin R.sup.1, L.sup.1, L.sup.2, V, L.sup.3 und R.sup.2 sind, wie in der Spezifikation definiert, die ein Enzym der Matrix metalloproteinase-13 hemmt und folglich für das Behandeln von von Krankheiten nützlich ist, resultierend aus MMP-13 vermitteltem Gewebezusammenbruch wie Osteoarthritis, rheumatoid Arthritis, Knorpelbeschädigung, psoriatic Arthritis, ankylosing spondylitis, Herzausfall, Atherosclerose, entzündliche Darmkrankheit, mehrfache Sklerose, altersgebundene macular Degeneration, chronische hemmende Lungenkrankheit, Asthma, periodontale Krankheiten, psoriasis, Krebs, und Osteoporose.

 
Web www.patentalert.com

< Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient

< Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4

> Combination therapy using interferon-tau

> Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

~ 00175